Firms In Pharmaceutical Industry Research Articles

Pharmaceutical Product Liability and the Propensity to Patent: An Empirical Firm-Level Investigation

Do different pharmaceutical product liability regimes in different countries induce innovation or can they lead to potentially socially undesirable outcomes? We exploit the variation in pharmaceutical liability and litigation rules across firms in pharmaceutical industry and countries to explain the firm-level propensity to innovate. Drawing on a large dataset from European Patent Office (EPO) covering over 9.950 pharmaceutical patents from 63 countries over the period 1991-2015, we compute the conditional probabilities of individual pharmaceutical firms to acquire a valid based patent on the validation outcomes and examine whether different liability regimes encourage or deter firm-level innovation. Our empirical strategy addresses firm-level idiosyncrasies, country-level unobserved effects and common technology shocks that potentially invoke omitted variable bias in the effects of liability regimes on the propensity to patent. Our investigation reveals that liability regimes combined with damage caps, broad statutory excuses and reversed burden of proof have a strong positive effect on the firm-level patent stock and a negative effect upon EPO patent validation rate. The evidence suggests that not all liability rules and related litigation procedures are created equal. Firms are systematically more likely to hold valid patents at the EPO when the liability and litigation rules are not complex and when the damage cap, broad statutory excuses and reversed burden of proof are introduced.

Critical Success Factors for Adopting Cloud Computing in the Pharmaceutical Manufacturing Companies

Cloud computing is a model for enabling ubiquitous, easy, and on-demand network access to a shared aggregation of configurable computing sources. Adopting of cloud computing in the pharmaceutical manufacturing is influenced by a group of critical success factors. Therefore, this paper depends on the technological-organizational-environmental (TOE) framework to explore the factors that influence on cloud computing adoption by pharmaceutical industry firms in Jordan through proposing a model for Pharmaceutical Manufacturing Companies. Complexity, compatibility, relative advantage, top management support, firm size, technical readiness, competitive pressure, and trading partner pressure, are the eight critical success factors that have been tested. A survey was utilized to collect data from 16 pharmaceutical manufacturing firms in the capital of Jordan- Amman. Relevant hypotheses were developed and examined by multiple regression analysis. The results of the data analysis generally support the suggested model. In summary, the results of this research have shown that all above-mentioned factors were found to have a significant influence on adoption of cloud computing for the pharmaceutical industry in Jordan. This finding of adoption in cloud computing in the pharmaceutical industry will help firms to take into consideration their information for technologies investments.

Analysis of Financial performance affecting Stock Price on Pharmaceutical Industry

This research is conducted to analyze the influence of stock price of firms in the pharmaceutical industry as listed in the JSX using financial ratios and based on the Gordon model approach. Methodology used in this research was Gordon model to know the stocks intrinsic value from each firm, then the comparison of market stock price, and analysis using regression analysis to know which factors affect stock price and how big the influence is. This research used six research variables; ROA, ROE, payout ratio, book value per share. and debt to equity ratio. The research population was pharmaceutical companies listed on the JSX until the end of 2004. It can be concluded that ROA, ROE,book value per share, and debt to equity has a very weak influence to stock price. Only payout ratio has the significant influence to stock price of firm in the pharmaceutical industry listed on the JSX. There is significant effect from return on asset, return on equity, payout ratio, book value per share and debt toequity ratio altogether to market price of firms in pharmaceutical industry.

What drives partners in industry-academia cooperation? A special consideration of reducing uncertainty through computational chemistry

A high degree of uncertainty is an inherent characteristic of innovation processes. In the chemical and pharmaceutical industry firms have traditionally relied on experimental trial and error in their R&D strategy. Against this background, computational chemistry provides the possibility to streamline the R&D process and accelerate development times. In this setting we employ a sample of 148 respondents to identify different types of scientists with respect to their attitudes towards industry-academia cooperation. We find two significantly distinct groups: 'The Pure Scientist' and 'The Pure Cooperator'. The characteristics of these types are further described and managerial implications are discussed.

Analysis of Riskiness of Pharmaceutical Industry Firms

Analysis of Riskiness of Pharmaceutical Industry Firms

Influences on R&D growth among Japanese pharmaceutical firms, 1975–1990

In this paper, we study changes in R&D expenditure of Japanese pharmaceutical manufacturers between 1975 and 1990. The analysis contributes to our understanding of firms' R&D strategy as a dynamic process. How competitors change their relative R&D positions, more than whether differences exist at one time, has a major impact on changes in competitive strength within technology-intensive industries. Understanding the dynamics of R&D expenditure is an important element in understanding why large firms do not always stay large and why industry leaders are sometimes dislodged by innovative followers. In addition, the study is intrinsically interesting because it helps us understand the changing nature of technological competition in an important global industry. Individual firms in the pharmaceutical industry are pursuing very different R&D investment strategies. Understanding the differences is critically important if we are to understand the potential strength of the firms in the future global pharmaceutical industry.